Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MelaOstrong: Melatonin and Osteogenic Loading for Osteopenia
NCT04233112Phase 1Completed
- Sponsor
- Duquesne University
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of melatonin in osteopenia (4 arms), sponsored by Duquesne University. Primary endpoints: Bone Mineral Density Femoral Neck at 12 months, Bone Mineral Density Total Hip at 12 months and 1 more. Started Jul 2020; status: completed.
02
Drugs
melatonin
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT04233112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233112.